Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures (Q37585099)

21 August 2017

1 reference

title

Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures (English)

1 reference

21 August 2017

0 references

Maurizio Bendandi

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

21 August 2017

published in

Nature Reviews Cancer

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

9

1 reference

21 August 2017

page(s)

675-681

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2717

21 August 2017

exact match

0 references

cites work

Anti-idiotype vaccines for human follicular lymphoma

1 reference

Antibody to a molecularly-defined antigen confined to a tumour cell surface

31 March 2020

1 reference

Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes

31 March 2020

1 reference

Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma

31 March 2020

1 reference

The role of idiotype vaccines in the treatment of human B-cell malignancies

31 March 2020

1 reference

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

31 March 2020

1 reference

Aiming at a curative strategy for follicular lymphoma

31 March 2020

1 reference

Myeloma proteins as tumor-specific transplantation antigens

31 March 2020

1 reference

Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response

31 March 2020

1 reference

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

31 March 2020

1 reference

Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses

31 March 2020

1 reference

Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

31 March 2020

1 reference

Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.

31 March 2020

1 reference

Prolonged idiotypic vaccination against follicular lymphoma.

31 March 2020

1 reference

Clinical benefit of idiotype vaccines: too many trials for a clever demonstration?

31 March 2020

1 reference

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma

31 March 2020

1 reference

Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins

31 March 2020

1 reference

Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure

31 March 2020

1 reference

Keyhole limpet hemocyanin: molecular structure of a potent marine immunoactivator. A review

31 March 2020

1 reference

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma

31 March 2020

1 reference

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

31 March 2020

1 reference

Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center

31 March 2020

1 reference

Future of idiotypic vaccination for B-cell lymphoma

31 March 2020

1 reference

Vaccines for lymphomas: idiotype vaccines and beyond

31 March 2020

1 reference

First proteasome inhibitor approved for multiple myeloma

31 March 2020

1 reference

A phase 2 study of bortezomib in relapsed, refractory myeloma

31 March 2020

1 reference

Revised response criteria for malignant lymphoma

31 March 2020

1 reference

Gastrosplenic fistula from Hodgkin's lymphoma

31 March 2020

1 reference

Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by anti-idiotype

31 March 2020

1 reference

Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies

31 March 2020

1 reference

Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials

31 March 2020

1 reference

Mouse x human heterohybridomas as fusion partners with human B cell tumors

31 March 2020

1 reference

Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development

31 March 2020

1 reference

Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma.

31 March 2020

1 reference

Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor.

31 March 2020

1 reference

Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells

31 March 2020

1 reference

Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma

31 March 2020

1 reference

Idiotype vaccination for lymphoma: moving towards optimisation

31 March 2020

1 reference

Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas

31 March 2020

1 reference

Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines

31 March 2020

1 reference

Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo

31 March 2020

1 reference

Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.

31 March 2020

1 reference

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype

31 March 2020

1 reference

Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy

31 March 2020

1 reference

Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein

31 March 2020

1 reference

12 December 2020

Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.

1 reference

12 December 2020

Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies

1 reference

12 December 2020

Feasibility of idiotype vaccination in relapsed B-cell malignancies

1 reference

12 December 2020

Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1

1 reference

12 December 2020

Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.

1 reference

12 December 2020

Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC2717

1 reference

21 August 2017

1 reference